In addition to those targeting genes of interest (Figure 2A), we screened 3 KRAS-amp cancer cell lines, including 2 cancer cell lines (KE-39 and YCC-1) and 1 patient-derived cell line (CAT12) (Figure 2, B–D). This evidence concerns the gene KRAS and cancer.